Literature DB >> 7004474

Indomethacin in rheumatoid arthritis: comparison of oral and rectal dosing.

N Baber, R Sibeon, E Laws, L Halliday, M Orme, T Littler.   

Abstract

1 Indomethacin 100 mg nightly for 1 week has been administered to 13 patients with rheumatoid arthritis by both oral and rectal routes in a double-blind, randomized, cross-over study. 2 Clinical assessments were performed at 09.00 and 14.00 h on the last 3 days of each active treatment period and compared to the results on the last 2 days of the placebo control period. 3 Indomethacin produced significant improvements in the clinical assessments at both 09.00 and 14.00 h compared to placebo but not differences were seen between the two routes of administration. 4 No significant difference was seen in the side effects experienced in the two periods. 5 The mean (+/- s.e. mean) plasma indomethacin concentration at 09.00 h in the oral period was 200.3 +/- 27.4 ng/ml, not significantly different from that in the suppository period (220.0 +/- 28.9 ng/ml). 6 Indomethacin 100 mg nightly by mouth is as effective as a 100 mg suppository and easier to administer.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7004474      PMCID: PMC1430096          DOI: 10.1111/j.1365-2125.1980.tb01775.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  10 in total

1.  INDOMETHACIN: STUDIES OF ABSORPTION AND OF THE USE OF INDOMETHACIN SUPPOSITORIES.

Authors:  L P HOLT; C F HAWKINS
Journal:  Br Med J       Date:  1965-05-22

2.  INDOMETHACIN SUPPOSITORIES.

Authors:  D L WOOLF
Journal:  Br Med J       Date:  1965-06-05

3.  Kinetics of indomethacin absorption, elimination, and enterohepatic circulation in man.

Authors:  K C Kwan; G O Breault; E R Umbenhauer; F G McMahon; D E Duggan
Journal:  J Pharmacokinet Biopharm       Date:  1976-06

4.  Indomethacin and naproxen suppositories in the treatment of rheumatoid arthritis.

Authors:  H Berry; D Swinson; J Jones; E B Hamilton
Journal:  Ann Rheum Dis       Date:  1978-08       Impact factor: 19.103

Review 5.  Evening indomethacin in the treatment of rheumatoid arthritis.

Authors:  E C Huskisson; R T Taylor; D Burston; P J Chuter; F D Hart
Journal:  Ann Rheum Dis       Date:  1970-07       Impact factor: 19.103

6.  Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis.

Authors:  D M Ritchie; J A Boyle; J M McInnes; M K Jasani; T G Dalakos; P Grieveson; W W Buchanan
Journal:  Q J Med       Date:  1968-07

7.  Clinical measurement of the anti-inflammatory effects of salicylates in rheumatoid arthritis.

Authors:  P L Boardman; F D Hart
Journal:  Br Med J       Date:  1967-11-04

8.  Gastric ulceration occurring during indomethacin therapy.

Authors:  R T Taylor; E C Huskisson; G H Whitehouse; F D Hart; D H Trapnell
Journal:  Br Med J       Date:  1968-12-21

9.  Pharmacokinetics of indomethacin.

Authors:  G Alván; M Orme; L Bertilsson; R Ekstrand; L Palmér
Journal:  Clin Pharmacol Ther       Date:  1975-09       Impact factor: 6.875

10.  Quantitative gas-liquid chromatographic method for the determination of indomethacin in biological fluids.

Authors:  R G Sibeon; J D Baty; N Baber; K Chan; M L Orme
Journal:  J Chromatogr       Date:  1978-06-01
  10 in total
  4 in total

1.  Suppositories for arthritis.

Authors:  J P Famaey
Journal:  Clin Rheumatol       Date:  1992-03       Impact factor: 2.980

2.  Pharmacokinetics of intraarticular indomethacin in patients with osteoarthritis.

Authors:  G Neander; L O Eriksson; E Wållin-Boll; H Ersmark; A Grahnen
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 3.  Protein binding as a primary determinant of the clinical pharmacokinetic properties of non-steroidal anti-inflammatory drugs.

Authors:  J H Lin; D M Cocchetto; D E Duggan
Journal:  Clin Pharmacokinet       Date:  1987-06       Impact factor: 6.447

4.  A clinical and pharmacokinetic study of indomethacin in standard and slow release formulations.

Authors:  K R Adams; L D Halliday; R G Sibeon; N Baber; T Littler; M L Orme
Journal:  Br J Clin Pharmacol       Date:  1982-08       Impact factor: 4.335

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.